Search company, investor...

Perclose

perclose.com

Founded Year

1992

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Perclose

Perclose was founded to develop medical devices for the percutaneous closure of the femoral access site following catheterization procedures. Perclose was acquired by Abbott Laboratories.

Headquarters Location

400 Saginaw Drive ArthroCare Corporation 680 Vaqueros Avenue Sunnyvale, CA 94085-3523

Redwood City, California, 94063,

United States

650-474-3000

Missing: Perclose's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Perclose's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Perclose News

Guided Delivery Systems Announces Senior Leaders and Company Name Change to Ancora Heart

Oct 31, 2016

Guided Delivery Systems Announces Senior Leaders and Company Name Change to Ancora Heart October 31, 2016 08:00 AM Eastern Daylight Time SANTA CLARA, Calif.--( BUSINESS WIRE )--Guided Delivery Systems Inc., a company developing a novel treatment to address heart failure and functional mitral regurgitation, today announced Jeffrey M. Closs has assumed the role of President and CEO and the company has completed a name change to Ancora Heart, Inc. Closs, who joined as President and CEO in November 2015, has an extensive background across cardiovascular medical devices, health policy and technology. Previously, he was the co-founder, President and CEO of Benu, Inc., an early innovator in risk-adjusted healthcare exchanges. The company was sold to PlanSource in 2015. Prior to co-founding Benu, Closs spent significant time in the cardiovascular industry as President and CEO at Fox Hollow Technologies, Inc., and as Vice President and International General Manager for Perclose. As part of the senior executive team at Perclose, he helped lead the company from its early formation through a successful IPO and ultimately to an acquisition by Abbott Laboratories. Prior to Perclose, Closs held sales, marketing and clinical positions with Devices for Vascular Intervention and Bentley/Edwards Labs. “Since joining the company, I have seen the significant opportunity for the AccuCinch® Ventriculoplasty System to address the unmet needs for treating heart failure and functional mitral regurgitation patients,” said Closs, President and CEO of Ancora Heart. “Our new name, Ancora Heart, better reflects our unique approach and mechanism of remodeling the left ventricle to address heart failure and functional mitral regurgitation.” “Jeff is a tremendous asset to the company and has had a year of significant accomplishments with the team,” said Bob Croce, Chairman of the Board. “Since assuming the role of Chairman in December 2013, I have been pleased with the progress we are making to advance AccuCinch as an innovative new concept and solution for heart failure and FMR treatment options.” Croce has significant healthcare experience having previously served 12 years as Company Group Chairman during his 36-year career at Johnson & Johnson. Roles included: Worldwide Franchise Chairman of Cordis, Worldwide Franchise Chairman for Ethicon Endo-Surgery, McNeil Pharmaceutical Vice President of Business Development and President of Ethicon, Inc. “I’m thrilled to be leading Ancora during this exciting time,” said Closs. “We look forward to building on a year of significant progress that included technical refinements to the AccuCinch system, implementation of a well-defined clinical and regulatory strategy, and expansion of enrollment in our clinical studies in both Europe and the United States.” About Ancora Heart Ancora Heart is a medical technology company developing the percutaneous AccuCinch® Ventriculoplasty System for the minimally invasive treatment of heart failure and functional mitral regurgitation (FMR). AccuCinch is intended to treat left ventricular remodeling and mitral annular dilatation that leads to heart failure and FMR. More information can be found at www.ancoraheart.com . Contacts

Perclose Frequently Asked Questions (FAQ)

  • When was Perclose founded?

    Perclose was founded in 1992.

  • Where is Perclose's headquarters?

    Perclose's headquarters is located at 400 Saginaw Drive, Redwood City.

  • What is Perclose's latest funding round?

    Perclose's latest funding round is Acq - P2P.

  • Who are the investors of Perclose?

    Investors of Perclose include Abbott, Morgenthaler Ventures and Three Arch Partners.

  • Who are Perclose's competitors?

    Competitors of Perclose include Surgiquest, Avalon Laboratories, Cambridge Endoscopic Devices, arstasis, BaroSense and 9 more.

Compare Perclose to Competitors

T
Therus

Therus is developing the Therus Acoustic Hemostasis System, a medical device designed for rapid, durable, noninvasive sealing of femoral artery access punctures following catheterization-laboratory procedures such as angiography and angioplasty.

E
Es Vascular

ES Vascular Ltd. developed first ever surgical stapling devices for endovascular surgery. These devices aim to transform vascular surgery by shortening procedural times, and by simplifying and potentially increasing the safety of the most common vascular interventions. The company is currently developing three product lines for open AAA, endovascular AAA and Femoro-Pop bypass procedures. Its first products are anticipated to enter the market in 2008.nCompany Snapshotn Started in 2000 in Israel by Prof. Shifrin together with group of engineers and leading vascular surgeons from the US and Europe;n Developed a ever vascular stapling technology for stapling synthetic grafts to the aortan Developed endovascular devices for EVAR and SFA procedures

S
Softscope Medical Technologies

Softscope Medical Technologies is developing a medical technology designed to facilitate the performance of endoscopic procedures.

M
Mst (Medical Smart Tools)

MST - Medical Smart Tools was founded in 2004 with the mission to develop image guided surgery technology solutions. The Company aims to improve laparoscopic and other minimally invasive surgical procedures and medical staff effectiveness, thus increasing hospital efficiencies, reducing surgical costs, and improving patient outcomes. MST is working within NGT, a private technological incubator in Nazareth, Israel. MST presents the market with a smart disposable Robotic Arm camera holder for laparoscopy, based on advanced image technology. The system is comprised of a computer-controlled mechanism for mechanical camera motivation, intuitive interface between the surgeon and the mechanical system. The company's R&D efforts are spearheaded by a core group of engineers with expertise in image processing, dynamics of mechanisms, multi-link systems and biomechanics. The Company is backed by strong and experienced management and professional medical advisors.

E
Embolic Protection

Devices for the prevention of embolic complications including stroke and heart attack during interventional vascular procedures. Acquired by Boston Scientific in 2001.

N
Neurosonix

NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.